Porky i almost doubted your knowledge, until you posted the motley article. I think I should sell avacta and buy it back at £5 AFTER they announce everything. Investing must have changed a lot since I last checked.
I think as soon as Avacta realised the GOV were not interested in implementing BAMS, they outsourced it to Bruker, who will look at various user cases for it, whilst Avacta focus on the mear term LFT opportunity. So many opportunities, it feels like Avacta are too small, young for this powerhouse Affimer platform, which really makes this the perfect takeover candidate. A GSK would have got a test out 6 months ago, not Avacta's fault, just shows we are in early.
After 10 years of holing this POS what's another 10 years. Although share offering is defo coming next.
Another benefit for SB is once your shares are up 100%, you can use the profit as the margin and take out your initial investment. With shares you would have to sell half, and any future gains would be half that of the SB. I'd also say not to have a stop loss as any big drop/market manipulation could wipe you out. If you can find shares that have limited downside, I think it's great. But IG have really hurt the small caps lately, does anyone know if other SB companies also tok lots of companies off the market?
I've had a drink and started thinking this:
The gov test will be affirmer based, via mologic's CE, branded as NHS, made by GAD and ODX.
Once Avacta get their own CE, they will start providing their test direct to other customers using BBI and Abindgon. Thoughts?
Matt I totally agree. Avacta is not a chart trade, this is all about the news and will react to the fundamentals. Add to that, MM manipulation which will cause shakeouts and incorrect price action, you cannot trade Avacta based on its chart.
So now im thinking maybe mologic see affirmers as a pivotal ingredient but will only have a limit supply from avacta amd also they would be reliant on avacta, so as a back up and reduce reliance on avacta, will be working woth Aptamer group. Could this actually be more validation of avactas tech?
I sold because of the Aptamer news, not because of the price correcting. I don't understand how mologic can have additonal capacity to take on aptamers, unless their are doubts with avacta. Based on AS never meeting deadlines i couldn't handle holding during this uncertainty. Lets face it, we still don't have an approved test.